Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Celltrion (068270) – Provisional Sales Results / 2024-08-07

Posted on August 7, 2024August 6, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) – Provisional Sales Results / 2024-08-07

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Celltrion reported its provisional Q2 2024 separate financial results, recording revenue of approximately KRW 973.2B and operating profit of approximately KRW 313.1B, representing a 987.57% QoQ increase in operating profit.

📊 [Key Disclosure Details & Financial Highlights]

  1. Q2 2024 Performance (Separate Basis)
  • Revenue: KRW 973.197B (+52.48% QoQ, +130.09% YoY)
  • Operating Profit: KRW 313.057B (+987.57% QoQ, +92.11% YoY)
  • Profit Before Income Tax Expense: KRW 306.154B (+520.66% QoQ, +73.81% YoY)
  • Net Profit: KRW 244.615B (+301.45% QoQ, +74.85% YoY)
  1. H1 2024 Cumulative Performance (Separate Basis)
  • Revenue: KRW 1,611.442B (+68.11% YoY)
  • Operating Profit: KRW 341.841B (-1.90% YoY)
  • Profit Before Income Tax Expense: KRW 355.481B (-8.99% YoY)
  • Net Profit: KRW 305.548B (-2.00% YoY)
  1. Historical Comparison Figures
  • Q1 2024: Revenue KRW 638.245B / Operating Profit KRW 28.785B / Net Profit KRW 60.933B
  • Q2 2023: Revenue KRW 422.964B / Operating Profit KRW 162.954B / Net Profit KRW 139.897B
  1. Information Provision Details
  • Provider: Celltrion IR Team
  • Target: Domestic and international investors, media, etc.
  • Date: 2024-08-07
  • Contact: IR Department (+82-1661-8722)
  • Note: Figures are based on Celltrion’s separate financial statements and are provisional, subject to change based on the final external audit results.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Comparison Between Separate and Consolidated Results and Verification of Audited Figures

This disclosure presents provisional operating results on a separate financial statement basis. Comparing these numbers with the consolidated results that include subsidiaries, as well as verifying final audited figures, is important for understanding the company’s overall financial health and comprehensive earnings performance. Detailed information can be verified in the separate and consolidated financial statement footnotes of the upcoming Half-Year Report.

📢 Disclaimer & Source Notice

Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) – Ex-Rights (Bonus Issue) / 2024-08-07
Next Post: [Disclosure] Celltrion (068270) – Additional Listing (Stock Option Exercise) / 2024-08-08

Related Posts

[Disclosure] Hana Micron (067310) – Investor Relations (IR) Holding / 2025-08-12 Disclosures
[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P13 SC in South Korea (Pediatric Crohn’s Disease) / 2024-09-30 Disclosures
[Disclosure] Samsung Electro-Mechanics (009150) – Advance Notice of Earnings Release / 2025-07-09 Semiconductors
[Disclosure] SK Hynix (000660) – Decision on New Facility Investment / 2024-07-26 Semiconductors
[Disclosure] Hanwha Ocean (042660) Amends Naval Vessel Contract Completion Date to June 2024 (Contract Value Unchanged at KRW 443.5B) Disclosures
[Disclosure] Hanwha Ocean (042660) – Decision on Lawsuit or Legal Proceedings (Claims Above Certain Amount) / 2025-01-15 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme